Categories

Author Archives

matthew holt

Quickbites: Equip; SameSky, Jenny Schneider (GC) & Calibrate

I’ve decided to try a new format for some interviews with digital health leaders. The other week I was at the Digital Health Innovation Summit in San Diego. I did a fair amount of tweeting from the conference but thought I’d also grab a few of the participants for some rapid fire interviews. They’re only 5 mins each but hopefully this “Quickbite” format will catch you up on some interesting players (even as they got buffeted a bit by the wind and the marine air corp!)–Matthew Holt

The Interviewees are. Kristina Saffran, CEO Equip; Abner Mason, CEO SameSky Health; Jennifer Schneider, ex-Livongo and now EIR at General Catalyst; & Isabelle Kenyon, CEO Calibrate: Their videos are below in order

Kristina Saffran, Equip
Abner Mason, SameSky Health
Jennifer Schneider, ex-Livongo, General Catalyst
Isabelle Kenyon, Calibrate

#HealthTechDeals Episode 9: Signify buys Caravan; Koneksa; Jasper; Vynca; Doximity

Jess & I are worried about Peleton’s CEO! Well that not worried. Signify Health buys Caravan Health for $250m ; Koneksa gets $45m; Jasper Health gets $25m; $30m for Vynca; & Doximity pays $82.5m for scheduling co Amion, while going gangbusters on its numbers. Matthew Holt

TRANSCRIPT

Jessica DaMassa:

Matthew Holt, you and our loyal listeners might recall how a few weeks ago I bring up the fact that no one is talking about Peloton and the fact that it’s killing TV characters left and right. Then what happens all of a sudden? Boom! Take out of Peloton. The stock has tanked. The CEO is gone. Thousands of people laid off. Am I the harboror of terrible things that are yet to come? It’s this episode, the February 10th episode of Health Tech Deals.

Continue reading…

Matthew’s health care tidbits: #What is insurance again?

Each week I’ve been adding a brief tidbits section to the THCB Reader, our weekly newsletter that summarizes the best of THCB that week (Sign up here!). Then I had the brainwave to add them to the blog. They’re short and usually not too sweet! –Matthew Holt

For my health care tidbits this week, I was reminded on Twitter that many Americans really don’t understand health insurance. A spine surgeon no less in this thread (no jokes about arrogance please) was telling me that he was paying ~$8,000 a year ($4,000 in insurance and $4,000 in deductible) before he got to “use” his insurance–which, as his medical costs were low, he never did. Others were complaining that the cost of employee premiums were over $20K. They all said they should keep the money and (presumably) pay cash when they do use the system. It’s true that most people don’t use their insurance. That’s the whole point. When you buy house insurance, you don’t expect your house to burn down. You are paying into a pool for the people whose house does burn down.

In the US we are on average spending $12k per person on health care each year. But spending on most people is way under that and for a few it’s way, way over. If you take the rough rule that 50% of the spending is on 10% of the people then 35 million people account for $2 trillion in spending–that’s ballpark $60,000 each. They are the ones with cancer, heart disease, complex trauma, etc, etc. The rest of us are “paying” our $4,000, $8,000 whatever, into the pool to cover that $60,000.

There are only two ways to lower that cost for the healthy who aren’t “using” their insurance. One is to exclude unhealthy people from that insurance pool, which makes the costs for everyone else much less. We did that for years with medical underwriting and it was nuts because it screws over the unhealthy. Fixing the pre-existing condition exclusions was the only bit of Obamacare everyone agrees on–even Trump. But now we are ten plus years into this new reality, some people have forgotten how bad it was before.

The other way is to reduce the costs in the system and lower that $4 trillion overall. How to do that is a much longer question. But it isn’t much connected to the concept of insurance.

Inside Wheel’s $150M Series C: CEO Talks “Long Game” for Stealthy Virtual Care Infrastructure Biz

By JESSICA DaMASSA, WTF HEALTH

Wheel’s CEO Michelle Davey says the white-label virtual care startup’s $150M Series C – led by notable health tech mega-funders Lightspeed Venture Partners & Tiger Global – is “really about the long-game.” We get into the details of this purposeful funding round and what it means for the future of Wheel, as well as the play-by-play analysis of what happened over the past 9 months, since the company closed its $50M Series B. (FYI: Wheel’s total funding is at $216 million to-date.)

Wheel is currently running behind-the-scenes for an undisclosed client list of brands, facilitating 1.6 million virtual visits a year for digital health companies, digital pharmacies, retailers, and, now, even traditional healthcare providers. That number is expected to triple by the end of 2022, and we get into what’s fueling that growth and whether or not Michelle believes that this institutional push toward online care will persist as the pandemic wans and the world continues re-opening.

Armed with this fresh funding, how will three-year-old Wheel continue to differentiate its offering from legacy telehealth infrastructure providers like Amwell and Teladoc? How will it win against their legacy relationships with legacy healthcare providers? Or, is Wheel’s big bet on the continued scaling of what Michelle calls “next generation healthcare”? Wheel has added A LOT of tech to its own infrastructure recently, providing asynchronous options, better clinician matching, more triaging and navigating, and, with this funding, are is now talking about adding “diagnostic services” to round out their service line. What, exactly are we talking about here in terms of business model evolution? Tune in and find out what this stealthy startup is up to!

THCB Gang Episode 80, Thursday Jan 27

Joining Matthew Holt (@boltyboy) on #THCBGang for an hour of conversation on the happenings in health care and beyond were regulars medical historian Mike Magee  (@drmikemagee) and writer Kim Bellard (@kimbbellard), and TWO special guests.

Shantanu Nundy @DrNundy  is Chief Medical Officer of Accolade and last year we had him on to talk about his book Care After Covid. This week, with Lisa Cooper and Kedar Mate he wrote in Jama adding “advancing health equity” as a new part of the “quintuple aim.”

Our second guest was Janae Sharp @CoherenceMed from the Sharp Index, which is dedicated to increasing awareness of and reducing physician suicide and burnout through support and data science

Were we ever going to be able to cover everything about physician burnout and health equity in just one hour? Yes, it was unlikely but we gave it our best shot!

The video is preserved below. If you’d rather listen to the episode, the audio is available from Friday as a weekly podcast available on our  iTunes & Spotify channels. 

Infermedica raises a big round and demos new product

Infermedica is a company that started by creating symptom checking and chatbot functionality in Poland back in 2012. It’s spread to delivering that patient-facing diagnosis functionality via API and now as preparation for a physician visit. Today they announce a $30m series B and demo their new product which helps prepare a visit, and integrates into the clinician workflow. I spoke with CEO Piotr Orzechowski and Chief Product Officer Tim Price–Matthew Holt.

Interview & Deep Dive into Summus Global

Summus Global is company with a very interesting model that gives a glimpse about the future of virtual care. It delivers online specialty care and much more to employers. You might think that means it is in the second opinion space, or in the care navigation space. And you’d be right, but not completely right. Julian Flannery the CEO tells me that it’s much more than that and has greater ambitions too. I took really deep dive into Summus with conversation with Julian and a thorough demo of the service from Dennis Purcell the COO–Matthew Holt

Medicare Advantage Is a Superior Program (Part two)

By GEORGE HALVORSON

Former Kaiser Permanente CEO George Halvorson has written on THCB on and off over the years, most notably with his proposal for Medicare Advantage for All post-COVID. He wrote a piece in Health Affairs last week arguing with the stance of Medicare Advantage of Don Berwick and Rick Gilfillan (Here’s their piece pt1, pt2). Here’s a longer exposition of his argument. We published part one last week so please read that first. This is part two – Matthew Holt

Medicare Advantage is better for the underserved

The African American and Hispanic communities who were particularly hard hit by those conditions and by the Covid death rates have been enrolling in significant numbers in Medicare Advantage plans.

The sets of people who were most damaged by Covid have chosen in disproportional numbers to be Medicare Advantage members. Currently 51 percent of the African Americans on Medicare are in Medicare Advantage plans and more than 60 percent of the Hispanic Medicare members will be on Medicare Advantage this year.

That disproportionate enrollment in Medicare Advantage surprises some people, but it really should not surprise anyone because the Plans have made special,  direct, and inclusive efforts to be attractive to people with those sets of care needs and have delivered better care and service than many of the new enrollees have ever had in their lives. 

The Medicare Advantage plans have language proficiency support competencies, and language requirements and capabilities that clearly do not exist anywhere for fee-for-service Medicare care sites. A combination of team care,  language proficiency, and significantly lower direct health care costs for each member has encouraged that pattern of enrollment as well.

The $1600 savings per person has been a highly relevant factor as more than twice as many of the lowest income Medicare members — people who make less than $30,000 a year — are now enrolled in Medicare Advantage plans.

Medicare Advantage’s critics tend to explicitly avoid discussing those enrollment patterns, and some of the most basic critics actually shamelessly say, with what must be at least unconscious malicious intent in various publications and settings, that the Medicare Advantage demographics for both ethnicity and income levels are a clone for standard Medicare membership. Those critics have said that  there is nothing for us to learn or see from any enrollment patterns or care practices based on those sets of issues.

Many people who discuss Medicare Advantage in media and policy settings generally do not focus on or even mention the people in our population who most need Medicare Advantage — the 4 million people who are now enrolled in the Special Needs Plans.

Special Needs Plans for Dual Eligibles

The Special Needs Plans take care of low-income people who have problematic levels of care needs and who very much need better care.

Continue reading…

Medicare Advantage Is a Superior Program (Part one)

By GEORGE HALVORSON

Former Kaiser Permanente CEO George Halvorson has written on THCB on and off over the years, most notably with his proposal for Medicare Advantage for All post-COVID. He wrote a piece in Health Affairs last week arguing with the stance of Medicare Advantage of Don Berwick and Rick Gilfillan (Here’s their piece pt1, pt2). Here’s a longer exposition of his argument. We are publishing part one today with part two coming soon – Matthew Holt

The evidence for Medicare Advantage being a superior program compared to standard fee-for-service Medicare is so overwhelming that anyone who cares about actual Medicare Patients or who cares about the financial future of Medicare should be strongly supporting having as many people as possible enrolled in that program as soon as we can effectively make that happen.

Compared to fee-for-service Medicare, Medicare Advantage has better benefits.

Compared to fee-for-service Medicare, Medicare Advantage has a better tool kit at multiple levels.

Medicare Advantage has team care, connected care, and electronically supported care processes — and we know beyond any debate or dispute that those advantages exist for Medicare Advantage over standard fee-for-service Medicare because fee-for-service Medicare does not pay for those sets of services and literally labels it billing fraud if a caregiver who provides team care in a patients home to prevent a congestive heart failure crisis or to keep a life threatening and function impairing asthma attack from happening sends a bill to standard Medicare for those services.

The superiority of Medicare Advantage is beyond question.

Standard fee-for-service Medicare has no quality care processes, no quality reports and no quality standards or expectations at all. Standard Medicare actually has absolutely no quality data and does not hold any provider accountable for the quality of the care they deliver.

Medicare Advantage has an extensive quality agenda and tracks more than 40 categories of quality and service at the plan level. Medicare Advantage plans build continuously improving programs around those Five-Star priorities and measures, and we know from our current reporting that even during Covid, the percentage of Medicare Advantage patients with cardiovascular disease who are currently on statin therapy went up from 80.86% of patients a year ago to 83.36% this year.

The ratings by the Medicare Advantage members for customer service by their plans went from 90.56% a year ago to 90.87% this year.

That is not a big improvement but having satisfaction numbers that start out that high actually go up during Covid days is an accomplishment and it is one of the reasons why we should be encouraging people to join the plans and its why fee-for-service Medicare is a measurably inferior approach for so many people.

Standard Medicare does not have a clue about who is getting their statin Medications and they officially don’t care.

In fact, some of the fee-for-service Medicare doctors and care sites who are paid only by the piece for care from the standard Medicare program actually often make more money when care fails, because when a patient has a major asthma crisis or a congestive heart failure crisis, that negative outcome for a patient can generate multiple medical fees and it can too often trigger a $10,000–$20,000 total additional cash flow to the caregivers whose care sites failed that patient by not helping improve the health of the patient before the crisis was triggered.

Why is Medicare Advantage’s purchasing system better?

Medicare Advantage plans are paid by Medicare by the month for each patient and they are not by the piece for each item of care.

Because Medicare Advantage plans are paid by the month for each patient, and must, by contract, provide complete care to each patient, it makes extremely good sense for the plans to help patients in ways that prevent asthma attacks and that prevent congestive heart failure crisis, and that avoid and help reduce the levels of blindness and amputations for their diabetic patients that can too easily happen to those patients if you don’t manage and guide that care.

The Medicare Advantage approach for all of those categories of care is obviously far better for the patients than the fee-for-service Medicare inadequacies in care.

Continue reading…

Health in Two Point 00 – The LAST Episode (247)

It’s the very last episode of Health in Two Point 00! (We’re not going away just changing the name next week). Six deals in 2 minutes! Embold Health gets $20m; Brainomix gets $21m; $25m for Zing Health; Quartet buys Innova Tel; Prolucent Health gets $11m; and Mightier gets $17m. And now we are done with 2021! And to announce the new name, we are wearing evening dress! – Matthew Holt

assetto corsa mods